Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fidaxomicin vs Vancomycin in CDAD (OPT-80-004)
NCT00468728Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of fidaxomicin in Clostridioides difficile infection (CDI) (2 arms), sponsored by Merck & Co. Primary endpoint: Cure Rate at End of Therapy at 10 days. Started Oct 2006; status: completed.
02
Drugs
fidaxomicin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT00468728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468728.